title: Is the WHI relevant to HRT started in the perimenopause?
abstract: The Women's Health Initiative (WHI) hormone replacement therapy (HRT) estrogen plus progestin (E+P) and estrogen-only arms are part of a large NIH-sponsored randomized controlled trial (RCT). Both arms were terminated prematurely after 5 and 8 yr, respectively. The E+P arm showed non-statistically significant increased incidences of cardiovascular events and breast cancer, whereas the E-only arm did not. Both arms showed an increased rate of thromboembolic events and stroke. Both arms showed protection against fractures and with protection against colon cancer only in the E+P arm. These results have been widely generalized as indicating a negative risk/benefit ratio for HRT in menopausal women. The WHI results are at odds with results of large epidemiological studies that showed protection against cardiovascular disease. Although the latter data are, in part, confounded by a "healthy user bias," much of the inconsistency may be explained by the fact that women in the latter studies initiated HRT at the menopausal transition, whereas the WHI trial was conducted in older women (mean age 63.3), who were, on average, approx 12 yr postmenopausal. In addition, older trials included women on either unopposed estrogen therapy (ERT) or cyclic HRT regimens. Whatever other forces may have been at work, observational and experimental evidence supports the conclusion that estrogen's atheropreventive effects predominate early, in the absence of vulnerable plaque to be ruptured or thrombotic episodes propagated by narrowed lumens and intravascular turbulence. On the contrary, age-related adverse effects of HRT may prevail once complex atheromas and luminal narrowing/irregularity are established. It is known that prevalence of subclinical "at-risk" atherosclerotic lesions increases in women during the first 5-10 yr after menopause. Furthermore, animal and clinical evidence supports the use of lower doses of estrogen than were employed in the WHI in older/longer postmenopausal women.
authors.affiliation: Kronos Longevity Research Institute, Phoenix, AZ, USA.
authors.forename: S Mitchell
authors.initials: SM
authors.lastname: Harman
authors.forename: Eliot A
authors.initials: EA
authors.lastname: Brinton
authors.forename: Thomas
authors.initials: T
authors.lastname: Clarkson
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Heward
authors.forename: Harvey S
authors.initials: HS
authors.lastname: Hecht
authors.forename: Richard H
authors.initials: RH
authors.lastname: Karas
authors.forename: Debra R
authors.initials: DR
authors.lastname: Judelson
authors.forename: Frederick
authors.initials: F
authors.lastname: Naftolin
mesh_terms: D001161:Arteriosclerosis / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003110:Colonic Neoplasms / Q000517:prevention & control; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008593:Menopause; D009316:National Institutes of Health (U.S.); D017698:Postmenopause; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000139:chemically induced / Q000453:epidemiology; D013923:Thromboembolism / Q000139:chemically induced / Q000453:epidemiology; D014481:United States; D016387:Women's Health
chemical_list: D004967:Estrogens; D011372:Progestins